AAAAAA
Results:
1-11
|
Results: 11
Authors:
DEPRE M
LO MW
VANHECKEN A
DELEPELEIRE I
HAND EL
LOWRY R
CONNOR JG
MURPHY MG
FEVERY J
DESCHEPPER PJ
Citation: M. Depre et al., MILD-TO-MODERATE HEPATIC INSUFFICIENCY DOES NOT AFFECT PHARMACOKINETICS AND PHARMACODYNAMICS OF TIROFIBAN, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4711-4711
Authors:
COPINSCHI G
LEPROULT R
VANONDERBERGEN A
CAUFRIEZ A
COLE KY
SCHILLING LM
MENDEL CM
DELEPELEIRE I
BOLOGNESE JA
VANCAUTER E
Citation: G. Copinschi et al., PROLONGED ORAL TREATMENT WITH MK-677, A NOVEL GROWTH-HORMONE SECRETAGOGUE, IMPROVES SLEEP QUALITY IN MAN, Neuroendocrinology, 66(4), 1997, pp. 278-286
Authors:
DELEPELEIRE I
REISS TF
ROCHETTE F
BOTTO A
ZHANG J
KUNDU S
DECRAMER M
Citation: I. Delepeleire et al., MONTELUKAST CAUSES PROLONGED, POTENT LEUKOTRIENE D-4-RECEPTOR ANTAGONISM IN THE AIRWAYS OF PATIENTS WITH ASTHMA, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 83-92
Authors:
SCHWARTZ JI
VANHECKEN A
DESCHEPPER PJ
DELEPELEIRE I
LASSETER KC
SHAMBLEN EC
WINCHELL GA
CONSTANZER ML
CHAVEZ CM
WANG DZ
EBEL DL
JUSTICE SJ
GERTZ BJ
Citation: Ji. Schwartz et al., EFFECT OF MK-386, A NOVEL INHIBITOR OF TYPE-1 5-ALPHA-REDUCTASE, ALONE AND IN COMBINATION WITH FINASTERIDE, ON SERUM DIHYDROTESTOSTERONE CONCENTRATIONS IN MEN, The Journal of clinical endocrinology and metabolism, 81(8), 1996, pp. 2942-2947
Authors:
EHRICH E
DALLOB A
VANHECKEN A
DEPRE M
DELEPELEIRE I
BRIDEAU C
HILLIARD D
TANAKA W
MUKHOPADHYAY S
SEIBOLD J
DESCHEPPER P
GERTZ B
Citation: E. Ehrich et al., DEMONSTRATION OF SELECTIVE COX-2 INHIBITION BY MK-966 IN HUMANS, Arthritis and rheumatism, 39(9), 1996, pp. 328-328
Authors:
SCHWARTZ J
VANHECKEN A
DELEPELEIRE I
WANG D
DEPRE M
DESCHEPPER P
GERTZ B
Citation: J. Schwartz et al., PHARMACODYNAMICS OF MK-386 - A NOVEL INHIBITOR OF 5-ALPHA-REDUCTASE TYPE-1, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 171-171
Authors:
VANHECKEN A
DEPRE M
DELEPELEIRE I
LASKIN O
AU T
WOOLF E
YEH KC
DESCHEPPER PJ
Citation: A. Vanhecken et al., HUMAN PHARMACOKINETICS AND TOLERABILITY OF L-697,639, A NONNUCLEOSIDEHIV-1 REVERSE-TRANSCRIPTASE INHIBITOR, International journal of clinical pharmacology research, 14(2), 1994, pp. 45-50
Authors:
VANHECKEN A
DEPRE M
SCHWARTZ JI
TJANDRAMAGA TB
WINCHELL GA
DELEPELEIRE I
NG J
DESCHEPPER PJ
Citation: A. Vanhecken et al., PLASMA-CONCENTRATIONS AND EFFECT ON TESTOSTERONE-METABOLISM AFTER SINGLE DOSES OF MK-0434, A STEROID-5 ALPHA-REDUCTASE INHIBITOR, IN HEALTHY-SUBJECTS, European Journal of Clinical Pharmacology, 46(2), 1994, pp. 123-126
Authors:
DEPRE M
FRIEDMAN B
VANHECKEN A
DELEPELEIRE I
TANAKA W
DALLOB A
SHINGO S
PORRAS A
LIN C
DESCHEPPER PJ
Citation: M. Depre et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ORAL DOSES OF MK-0591, A 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR, Clinical pharmacology and therapeutics, 56(1), 1994, pp. 22-30
Authors:
PEERLINCK K
ARNOUT J
DELEPELEIRE I
GOLDBERG M
FITZPATRICK V
VERMYLEN J
Citation: K. Peerlinck et al., COMBINED EFFECT OF ASPIRIN AND MK 383 (L-700,462), A SELECTIVE GPIIB IIIA ANTAGONIST, IN HEALTHY-VOLUNTEERS/, Thrombosis and haemostasis, 69(6), 1993, pp. 560-560
Authors:
PEERLINCK K
DELEPELEIRE I
GOLDBERG M
FARRELL D
BARRETT J
HAND E
PANEBIANCO D
DECKMYN H
VERMYLEN J
ARNOUT J
Citation: K. Peerlinck et al., MK-383 (L-700,462), A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB IIIA ANTAGONIST, IS ACTIVE IN MAN/, Circulation, 88(4), 1993, pp. 1512-1517
Risultati:
1-11
|